secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001689548-23-000126
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis posts Q2 net loss $34.3M, plans ulixacaltamide Phase 3 after FDA meeting
-------------------------------------------------------------------------------

- Q2 net loss $34.3M, cash $124.3M; cash runway into Q1 2025 from June offering net $63.4M.
- Ulixacaltamide: FDA EOP2 meeting confirms Phase 3 plan; two studies starting Q4 2023, mADL11 primary endpoint, 60 mg, 12 weeks.
- PRAX-628 Phase 1 EEG showed pharmacodynamic activity at all doses; Phase 2 PPR study topline H2 2023; focal epilepsy Phase 2 H1 2024.
- Net loss $34.3M in Q2 2023 vs $60.2M in Q2 2022; R&D expenses $25.6M down from $43.6M.
- R&D Portfolio Day on Oct 2, 2023 to detail Phase 3 program for ulixacaltamide and additional Essential1 data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954823000126/0001689548-23-000126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954823000126/prax-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001689548-23-000126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer